Company Website:
http://www.foundationmedicine.com
CAMBRIDGE, Mass. -- (Business Wire)
Foundation
Medicine, Inc. (NASDAQ:FMI) today announced that it will provide a
live video webcast and conference call for its Investor & Analyst Day on
September 15, 2015. At the event, members of the Foundation Medicine
management team will discuss the company’s five-year strategic vision
for transforming cancer care and the significance of molecular
information as a driver of the company’s future growth and value.
Investor & Analyst Day Webcast and Conference Call Details
Date:
|
|
|
Tuesday, September 15, 2015
|
Time:
| | |
1:00-4:30p.m. ET
|
Webcast:
| | |
The video webcast and slide presentation accompanying the
conference call can be accessed at www.investors.foundationmedicine.com.
|
Telephone:
| | |
Domestic callers, dial 877-633-4016
|
| | |
International callers, dial 914-495-8535
|
| | |
Access code for both domestic and international callers: 23905461
|
Archives of the video and audio webcasts will be available in the
investors section of the company’s website at investors.foundationmedicine.com.
The replays will be available shortly after the conclusion of the event
and will be archived on the company's website following the call.
About Foundation Medicine
Foundation Medicine (NASDAQ:FMI) is a molecular information company
dedicated to a transformation in cancer care in which treatment is
informed by a deep understanding of the genomic changes that contribute
to each patient's unique cancer. The company's clinical assays,
FoundationOne® for solid tumors and FoundationOne® Heme for hematologic
malignancies and sarcomas, provide a comprehensive genomic profile to
identify the molecular alterations in a patient's cancer and match them
with relevant targeted therapies and clinical trials. Foundation
Medicine's molecular information platform aims to improve day-to-day
care for patients by serving the needs of clinicians, academic
researchers and drug developers to help advance the science of molecular
medicine in cancer. For more information, please visit http://www.FoundationMedicine.com
or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® and FoundationOne®
are registered trademarks of Foundation Medicine, Inc.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements regarding the information to
be presented by Foundation Medicine and the ability of molecular
information to drive growth and value for Foundation Medicine. All such
forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, the risks described under the caption "Risk Factors" in Foundation
Medicine's Quarterly Report on Form 10-Q for the three months ended June
30, 2015, which is on file with the Securities and Exchange Commission,
as well as other risks detailed in subsequent filings with
the Securities and Exchange Commission. All information in this press
release is as of the date of the release, and Foundation
Medicine undertakes no duty to update this information unless required
by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150831005067/en/
Contacts:
Media Contact:
Pure Communications, Inc.
Dan Budwick,
973-271-6085
dan@purecommunicationsinc.com
or
Investor
Contacts:
Susan Hager, 617-418-2258
ir@foundationmedicine.com
or
Matt
Clawson, 949-370-8500
matt@purecommunicationsinc.com
Source: Foundation Medicine, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.